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Dear Editor, 20 
We read with interest the recent paper detailing the pharmacokinetics of lamotrigine by van 21 
Dijkman et al1 and would like to congratulate the authors for compiling such a comprehensive 22 
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dataset, which they have used to evaluate apparent clearance (CL/F) changes from young infants 23 
to elderly adults. In particular these results are important in patients aged younger than 2 years for 24 
whom the drug is currently unlicensed. We note that an extensive erratum2 has attempted to 25 
correct the interpretation of the proposed dosing guidelines, although recommendations for 26 
patients with different co-medications would have been useful. Before considering dose guidelines 27 
derived from the model however, we feel there is a more fundamental question on the underlying 28 
assumptions in model that warrants further discussion; namely the proposed function to describe 29 
changes in CL/F with age. 30 
In Figure 1 we have plotted the change in predicted values of CL/F with post natal age (PNA) as 31 
reported by the authors, using a continuous function to predict typical weight for age3. Here it can 32 
be seen that CL/F peaks at a post-menstrual age (PMA) of approximately 110 weeks (PNA of 1.3 33 
years), then declines, and does not reach the same rate again until approximately 280 weeks PMA 34 
(PNA of 4.6 years). Between us we have extensive experience of modelling pharmacokinetic 35 
studies over large age ranges4–8, analysed how clearance in general changes for thousands of 36 
hypothetical drugs (e.g. see Calvier et al9 in this journal), and systematically reviewed clearance 37 
maturation functions in children10,11. The authors describe an extremely rare (possibly the first) 38 
case of decreasing CL/F with increasing age in infants and young children. Since CL/F determines 39 
steady-state concentration, and in this case maintenance dose, it is important that this change in 40 
CL/F with age is further explored. There are several possible explanations: 41 
Firstly, the arbitrary step function used to describe decreasing CL/F with age above 65 years may 42 
be causing an under-estimation of the true young adult value, and hence the dematuration function 43 
the authors report is merely a result of this under-estimate exacerbated by limited data in children 44 
aged 4-12 years. A more granular breakdown of goodness-of-fit to age groups of less than 1, 1-2, 45 
3-4 year olds and 12-30 year olds would show whether model fit was consistent amongst each age 46 
group. 47 
A second possibility is that bioavailability (F) is for some reason lower in infants taking the 48 
immediate release formulation, consequently making CL/F seem high. This does seem unlikely 49 
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since immediate and extended release formulations have been reported to be bioequivalent12, and 50 
lamotrigine is generally well absorbed, but changes in bioavailability with age cannot be ruled out. 51 
A third possibility, and one we think most likely, is that drug-drug interactions are causing 52 
confounding given that different age groups had different co-medication frequencies. Re-fitting the 53 
model to data only in patients not taking carbamazepine, phenytoin or valproic acid and re-54 
evaluating maturation parameters would determine this. Such an analysis would give confidence 55 
that the relative contribution of maturation and drug-drug interactions are correctly captured by the 56 
model. Further insight may also be achieved through PBPK analysis which may predict how CL/F 57 
could change with both age and in the presence of drug-drug interactions. 58 
This finding of decreasing CL/F with increasing age in infants and young children is a novel 59 
unexpected result, and further exploration to confirm whether it is a real phenomenon, and if so 60 
why it happens with lamotrigine, is required. 61 
Figure Legend 62 
Figure 1: Plot of lamotrigine CL/F versus age estimated by van Dijkman et al1 63 
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